Join us at ESHG 2025 for a lunch-and-learn and cutting-edge proteomics
Milan, Italy | May 24–27 | Booth 438
Uncover disease mechanisms and develop more effective therapeutic strategies at the
European Society of Human Genetics 2025 Annual Meeting.
Visit us at Booth 438 to find out how SomaScan™ technology can provide the most comprehensive approach to understanding health and disease. The high-plex proteomic analysis of the SomaScan Assay can be combined with genomic approaches to enable a more complete understanding of biological systems, disease origins and effective treatments, and identify relevant new drug and therapy targets. Learn more about ESHG 2025 here.
Why stop by?
- Expand your research capabilities: The SomaScan 11K Assay can now be run with human cerebrospinal fluid, and cell and tissue samples – meaning researchers can detect and quantify low-abundance proteins accurately, which is critical for identifying potential biomarkers and therapeutic targets. Learn more
- Ensure precision and trust your data: A new independent head-to-head comparison of precision demonstrates that the SomaScan Assay effectively scales protein measurements when other technologies cannot, while Nature has published corrected results from a study comparing two high-throughput proteomic platforms. Learn more
- Accelerate pharmacogenomics with microfluidics-based qPCR: Streamline your studies with 2x the speed and a single high-throughput workflow that consolidates multiple assays into one experiment. Learn more
Industry Education Session
Proteomics for Precision Healthcare
This industry education session will explore the application of different omic technologies that are now feasible at population scale. Julia Carrasco-Zanini-Sanchez, PhD, Postdoctoral Research Assistant in Computational Genomics and Multi-omics at Queen Mary University of London, will present examples of how the integration of different omics layers can help advance precision medicine across diverse populations.
Monday, March 26 | 12:00–1:00 pm | Room Amber 3
Poster Session
Is There Anything in the Swamp? A Credibility Assessment of Biologic Signals from Non-Secreted Low-Abundance Proteins Measured in Human Plasma
The expansion of proteomic multiplexing now includes the measurement of non-secreted low-abundance proteins. Because the mechanism for the presence of these proteins in plasma is unclear, the biological significance of this fraction of the proteome has been questioned. This poster presents methods to evaluate this question by seeking to determine if proteogenomic associations are present in the non-secreted, low-abundance fraction of the proteome and if this fraction contains other biologically relevant information.
Sunday, May 25 | 4:00–5:00 pm | Exhibition Hall
Meet the Biomark™ X9 System for High-Throughput Genomics
This system allows you to get big answers with micro-sized technology. This versatile benchtop platform delivers thousands of nanoliter-scale reactions in a single run, providing speed, scalability and walk-away automation that enable efficient genomic testing and the investigation of the relationship between a specific gene profile and a novel drug. Help facilitate PGx studies at 2x the speed with a single high-throughput workflow that consolidates multiple assays into one experiment.
